Efficacy and tolerability of the perindopril/indapamide combination therapy for hypertension: The PRIMUS study

Current Medical Research and Opinion

Volumn 22, Issue 9, 2006, Pages 1849-1858

  Holzgreve, Heinrich ^a   Risler, Teut ^b   Trenkwalder, Peter ^c  

^a Kardiologische Praxis   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c Klinikum Starnberg   (Germany)

Author keywords

Combination drug therapy; Hypertension; Indapamide; Perindopril; Risk factors

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INDAPAMIDE; PERINDOPRIL;

ADULT; AGED; ALLERGIC RHINITIS; ALLERGY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENERAL PRACTITIONER; GERMANY; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; LEG EDEMA; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; NAUSEA; OBSERVATIONAL STUDY; OPEN STUDY; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; TACHYCARDIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; INDAPAMIDE; MALE; MIDDLE AGED; PERINDOPRIL; PROSPECTIVE STUDIES;

EID: 33748995406     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X132433     Document Type: Article

References (32)

1. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72
3. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004;43:10-7
4. Materson BJ, Reda DJ, Cushman WC, Henderson WG. Results of combination anti-hypertensive therapy after failure of each of the components. Department of Veterans Affairs Cooperative Study Group on Anti-hypertensive Agents. J Hum Hypertens 1995;9:791-6
5. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-62
6. The ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97
7. Weber MA, Julius S, Kjeldsen SE, Brunner HR, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004;363:2049-51
8. Dahlof B, Hansson L, Lindholm LH, Schersten B, et al. Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) analyses performed up to 1992. Clin Exp Hypertens 1993;15:925-39
9. Materson BJ, Reda DJ, Williams D. Lessons from combination therapy in Veterans Affairs Studies. Department of Veterans Affairs Cooperative Study Group on antihypertensive agents. Am J Hypertens 1996;9:187S-91
10. Cushman WC, Ford CE, Cutler JA, Margolis KL, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002;4:393-404
11. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003
12. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805-16
13. Preterax® 2 mg/0.625 mg tablet. European summary of product characteristics. Servier International, Neuilly sur Seine, France, 2003
14. Mogensen CE, Viberti G, Halimi S, Ritz E, et al. Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension 2003;41:1063-71
15. Dahlof B, Gosse P, Gueret P, Dubourg O, et al. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J Hypertens 2005;23:2063-70
16. Mourad JJ, Waeber B, Zannad F, Laville M, et al. Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach. J Hypertens 2004;22: 2379-86
17. Mallion JM, Chamontin B, Asmar R, De Leeuw PW, et al. Twenty-four-hour ambulatory blood pressure monitoring efficacy of perindopril/indapamide first-line combination in hypertensive patients: the REASON study. Am J Hypertens 2004;17:245-51
18. Castaigne A, Chalmers J, Morgan T, Chastang C, et al. Efficacy and safety of an oral fixed low-dose perindopril 2 mg/indapamide 0.625 mg combination: a randomized, double-blind, placebo-controlled study in elderly patients with mild to moderate hypertension. Clin Exp Hypertens 1999;21: 1097-110
19. Chanudet X, De Champvallins M. Antihypertensive efficacy and tolerability of low-dose perindopril/indapamide combination compared with losartan in the treatment of essential hypertension. Int J Clin Pract 2001;55:233-9
20. Chalmers J, Castaigne A, Morgan T, Chastang C. Long-term efficacy of a new, fixed, very-low-dose angiotensin-converting enzyme-inhibitor/diuretic combination as first-line therapy in elderly hypertensive patients. J Hypertens 2000;18:327-37
21. Asmar RG, LondonGM, O'Rourke ME, Safar ME. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. Hypertension 2001;38:922-6
22. Laurent S. Clinical benefit of very-low-dose perindopril-indapamide combination in hypertension. J Hypertens Suppl 2001;19:S9-14
23. de Luca N, Mallion JM, O'Rourke MF, O'Brien E, et al. Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination: the REASON echocardiography study. Am J Hypertens 2004;17:660-7
24. Bi Preterax® 4 mg/1.5mg tablet. European summary of product characteristics. Servier International, Neuilly sur Seine, France, 2002
25. Waeber B. Very-low-dose combination: a first-line choice for the treatment of hypertension? J Hypertens Suppl 2003;21:S3-10
26. Waeber B. Targeting systolic blood pressure: the key to controlling combined systolic/diastolic hypertension. Am J Hypertens [in press]
27. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157:2413-46
28. Chalmers J. Trials on blood pressure-lowering and secondary stroke prevention. Am J Cardiol 2003;91:3G-8
29. PROGRESS Collaborative group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41
30. Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. PROGRESS Collaborative Group. Eur Heart J 2003;24:475-84
31. The CAFÉ Investigators. Differential impact of blood pressure lowering drugs on central aortic pressure and clinical outcomes. Principal results of the Conduit Artery Function Evaluation Study: The (CAFÉ) Study. Circulation 2006;113:1213-25
32. Safar ME, Vaisse B, Blacher J, Rudnichi A, et al. Pulse pressure monitoring of open antihypertensive therapy. Am J Hypertens 2004;17:1088-94